Ixabepilone
- Generic Name
- Ixabepilone
- Brand Names
- Ixempra
- Drug Type
- Small Molecule
- Chemical Formula
- C27H42N2O5S
- CAS Number
- 219989-84-1
- Unique Ingredient Identifier
- K27005NP0A
- Background
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue ...
- Indication
用于在其他化学治疗均失效后作为治疗晚期乳腺癌的药物。
- Associated Conditions
- Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer
- Associated Therapies
- -
Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2013-03-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00182702
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-03-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00182767
- Locations
- 🇺🇸
Women's Cancer Care Associates LLC, Albany, New York, United States
🇺🇸Montefiore Medical Center - Moses Campus, Bronx, New York, United States
🇺🇸University of Connecticut, Farmington, Connecticut, United States
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 35
- Registration Number
- NCT00162136
- Locations
- 🇺🇸
University Of Maryland, Baltimore, Maryland, United States
🇺🇸The Cancer Institute Of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT00095979
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 29
- Registration Number
- NCT00096317
- Locations
- 🇺🇸
Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 124
- Registration Number
- NCT00087139
- Locations
- 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸Saint Luke's Regional Medical Center, Sioux City, Iowa, United States
🇺🇸Methodist Medical Center of Illinois, Peoria, Illinois, United States
BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
- Conditions
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- R-Pharm
- Registration Number
- NCT00004927
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
- First Posted Date
- 2004-03-26
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 125
- Registration Number
- NCT00080262
- Locations
- 🇸🇪
Local Institution, Stockholm, Sweden
Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT00079326
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2004-02-27
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT00022542
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.